Paul, talk like a CEO...please. I really, really hate to be picky on this point I’ve made before, but do you see the difference in the statements below? Each are from a biotech CEO talking about a recent development. I also added the Marsolais scripted PR from the release.
Sutro CEO Statement:
“The encouraging safety and preliminary efficacy clinical data presented at ASH on STRO-001 for the treatment of late-line NHL further validates our platform and unique approach to ADC design, creating potential first-in-class and/or best-in-class therapeutic candidates.”
Immunomedics CEO Statement:
“We are delighted to witness the clinically meaningful survival benefit Trodelvy is bringing to mTNBC patients. These outstanding results have inspired us to fully demonstrate the potential of this valuable new treatment to improve the outlook of cancer patients worldwide,” commented Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics.
THTX CEO Statement:
Lvesque said by targeting the SORT1+ receptor, the compound “concentrates the cytotoxic medicine into the cancer cell and spares the healthy cells around so this is a very, very mindboggling approach to it.”
THTX CMO in Press Release:
“…These data also support that TH1902 has the potential to have an improved safety profile at therapeutic doses in comparison to standard cytotoxics. Most importantly, these findings give hope that we may finally be able to tackle hard-to-treat cancers with a more effective and better-tolerated treatment”, said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.”
…”mindboggling”, really? I just think a CEO should not use such hyperbolic, inexact, non-executive (to say it politely) terms like that and should instead be using the few words they get to use words that are convincing, strategic, and forward-thinking.
Why not say, “…and spares the healthy cells around it. In so doing this technology, which has broad applications beyond this one cancer, has the potential to be an entirely new approach to tackle these difficult cancers and improving the patient’s survivability by a multiple versus current standards. Our technology is not only thoroughly unique, but proprietary to Theratechnologies, and has the potential to be the best-in-class option for many heavily treated cancers given the high tolerability we’ve seen in our pre-clinical studies, the way it works, and our ability to use established chemo drugs as the payload in our trojan horse approach. To say we are excited is an understatement.
I hope he can start talking like a CEO and not a GenZ Fan-Boy. Sorry to be so persistent on this and I do not at all mean to be rude. But you can see from the above comparison that it really seriously stands out and not in a good way. Once you become the CEO, you should not be thinking in the salesman-ship terms and using over the top words that don’t have much of a meaning in investor or corporate strategy circles. Use serious terms to push your factual points out there for all the stakeholders to understand clearly. Mindboggling is not a term you'll hear many CEO's use, except in the cannabis industry.